TMT labeling and LC-MS/MS strategy to quantify differentially abundant proteins among COVID-19 patients

ABSTRACT: Coronavirus Disease 2019 (COVID-19) is characterized by a dysregulated host response. Proteomic studies have shed light in its complex pathogenesis, but there are few studies using cells, such as peripheral blood mononuclear cells (PBMCs). Here, we used TMT-based quantitative proteomics to characterize PBMCs from COVID-19 patients along their clinical course. Blood samples were collected prospectively from 29 patients with COVID-19 (confirmed by PCR in a nasopharynx swab) and 11 healthy volunteers (HVs), between May and September 2020. Samples were obtained at the first day of admission (D0; n=30), after seven days of hospitalization (D7; n=17), and 31 days after hospital discharge (Convalescent Sample; CS30; n=15). Protein extraction, quantification, reducing/alkylating, methanol/chloroform precipitations, digestion, and TMT Labeling were performed in PBM. The mass spectrometric data were acquired in a Orbitrap Fusion Lumos and data analysis was performed in Proteome Discoverer and imported to the R software environment for further analysis.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Reinaldo Salomao   Giuseppe Leite  

PROVIDER: MSV000091319 | MassIVE | Fri Feb 17 12:18:00 GMT 2023

SECONDARY ACCESSION(S): PXD040245

REPOSITORIES: MassIVE